0001628280-24-044196 | 10-Q | XBRL Viewer | Intracellular Therapies INC

Right of Use Assets and Lease Liabilities

9 Months Ended

Sep. 30, 2024

Right of Use Assets and Lease Liabilities

In 2014, the Company entered into a long-term lease with a related party, which, as amended, provided for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium-related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASC Topic 842, Leases, for accounting purposes. In September 2018, the Company further amended the lease to obtain an additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In May 2024, the Company entered into a long-term lease of office space in Bedminster, New Jersey. The lease has a term of 5.7 years ending in February 2030.

The Company has also entered into agreements (the “Vehicle Leases”) with providers (the “Lessors”) to acquire motor vehicles for certain employees. The Vehicle Leases provide for individual vehicle leases, which at each lease commencement was determined to qualify for operating lease treatment. The contractual period of each lease is 12 months, followed by month-to-month renewal periods. The Company estimates the lease term for each vehicle to be 12 months. Leases which the Company determined to have a lease term of 12 months or less will be treated as short-term in accordance with the accounting policy election and are not recognized on the balance sheet. Each lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.75 million letter of credit that the related Lessor may draw upon in the event the Company defaults on the related Vehicle Leases, which has been recorded as restricted cash on the condensed consolidated balance sheets.

The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2024 and December 31, 2023:


	September 30, 2024		December 31, 2023
Other information
Weighted average remaining lease term	4.7 years		5.3 years
Weighted average discount rate	8.82	%	9.07	%

The following table presents the lease cost for the nine-month periods ended September 30, 2024 and 2023 (in thousands):


	Nine Months Ended September 30,
	2024		2023
Lease cost
Operating lease cost	$	3,027	$	2,921
Variable lease cost	1,254		1,130
Short-term lease cost	1,854		1,757
	$	6,135	$	5,808

Maturity analysis under the lease agreements is as follows (in thousands):


Three months ending December 31, 2024	$	1,112
Year ending December 31, 2025	4,436
Year ending December 31, 2026	4,513
Year ending December 31, 2027	4,573
Year ending December 31, 2028	4,707
Thereafter	2,457
Total	21,798
Less: Present value discount	(4,089)
Total operating lease liability	17,709
Less: Current portion	(4,203)
Operating lease liabilities, non-current	$	13,506

Inventory (Tables)

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Schedule of Inventory, Current

Inventory consists of the following (in thousands):


	September 30, 2024		December 31, 2023
Raw materials	$	30,479	$	38,621
Work in process	13,048		4,277
Finished goods	10,491		7,370
Total	54,018		50,268
Less: Current portion	(23,539)		(11,647)
Total inventory, non-current	$	30,479	$	38,621

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2022		94,829,794
Beginning balance at Dec. 31, 2022	$ 656,070	$ 9	$ 2,137,737	$ (1,477,486)	$ (4,190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options and issuances of restricted stock (in shares)		849,827
Exercise of stock options and issuances of restricted stock	3,640	$ 1	3,639
Stock issued for services (in shares)		408
Stock issued for services	22		22
Share-based compensation	10,439		10,439
Net loss	(44,053)			(44,053)
Other comprehensive gain (loss)	1,492				1,492
Ending balance (in shares) at Mar. 31, 2023		95,680,029
Ending balance at Mar. 31, 2023	627,610	$ 10	2,151,837	(1,521,539)	(2,698)
Beginning balance (in shares) at Dec. 31, 2022		94,829,794
Beginning balance at Dec. 31, 2022	656,070	$ 9	2,137,737	(1,477,486)	(4,190)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(111,095)
Ending balance (in shares) at Sep. 30, 2023		96,225,617
Ending balance at Sep. 30, 2023	600,681	$ 10	2,190,587	(1,588,581)	(1,335)
Beginning balance (in shares) at Mar. 31, 2023		95,680,029
Beginning balance at Mar. 31, 2023	627,610	$ 10	2,151,837	(1,521,539)	(2,698)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options and issuances of restricted stock (in shares)		402,994
Exercise of stock options and issuances of restricted stock	8,585		8,585
Stock issued for services (in shares)		364
Stock issued for services	23		23
Share-based compensation	13,226		13,226
Net loss	(42,784)			(42,784)
Other comprehensive gain (loss)	430				430
Ending balance (in shares) at Jun. 30, 2023		96,083,387
Ending balance at Jun. 30, 2023	607,090	$ 10	2,173,671	(1,564,323)	(2,268)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options and issuances of restricted stock (in shares)		141,780
Exercise of stock options and issuances of restricted stock	2,581		2,581
Stock issued for services (in shares)		450
Stock issued for services	24		24
Share-based compensation	14,311		14,311
Net loss	(24,258)			(24,258)
Other comprehensive gain (loss)	933				933
Ending balance (in shares) at Sep. 30, 2023		96,225,617
Ending balance at Sep. 30, 2023	600,681	$ 10	2,190,587	(1,588,581)	(1,335)
Beginning balance (in shares) at Dec. 31, 2023		96,379,811
Beginning balance at Dec. 31, 2023	591,424	$ 10	2,208,470	(1,617,160)	104
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options and issuances of restricted stock (in shares)		1,097,668
Exercise of stock options and issuances of restricted stock	9,989		9,989
Stock issued for services (in shares)		339
Stock issued for services	23		23
Share-based compensation	13,843		13,843
Net loss	(15,247)			(15,247)
Other comprehensive gain (loss)	(534)				(534)
Ending balance (in shares) at Mar. 31, 2024		97,477,818
Ending balance at Mar. 31, 2024	599,498	$ 10	2,232,325	(1,632,407)	(430)
Beginning balance (in shares) at Dec. 31, 2023		96,379,811
Beginning balance at Dec. 31, 2023	591,424	$ 10	2,208,470	(1,617,160)	104
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(57,791)
Ending balance (in shares) at Sep. 30, 2024		105,998,786
Ending balance at Sep. 30, 2024	1,144,826	$ 11	2,818,137	(1,674,951)	1,629
Beginning balance (in shares) at Mar. 31, 2024		97,477,818
Beginning balance at Mar. 31, 2024	599,498	$ 10	2,232,325	(1,632,407)	(430)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued (in shares)		7,876,713
Common shares issued	543,086	$ 1	543,085
Exercise of stock options and issuances of restricted stock (in shares)		270,026
Exercise of stock options and issuances of restricted stock	2,093		2,093
Stock issued for services (in shares)		345
Stock issued for services	23		23
Share-based compensation	16,370		16,370
Net loss	(16,220)			(16,220)
Other comprehensive gain (loss)	(238)				(238)
Ending balance (in shares) at Jun. 30, 2024		105,624,902
Ending balance at Jun. 30, 2024	1,144,612	$ 11	2,793,896	(1,648,627)	(668)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options and issuances of restricted stock (in shares)		373,638
Exercise of stock options and issuances of restricted stock	6,734		6,734
Stock issued for services (in shares)		246
Stock issued for services	18		18
Share-based compensation	17,489		17,489
Net loss	(26,324)			(26,324)
Other comprehensive gain (loss)	2,297				2,297
Ending balance (in shares) at Sep. 30, 2024		105,998,786
Ending balance at Sep. 30, 2024	$ 1,144,826	$ 11	$ 2,818,137	$ (1,674,951)	$ 1,629

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on its consolidated financial statements and related disclosures.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Significant Accounting Policies	Significant Accounting Policies The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investment securities held at financial institutions. For the nine-month period ended September 30, 2024, 98% of product sales were generated from three major industry wholesalers. Three individual customers accounted for approximately 37%, 33%, and 28% as well as 36%, 32%, and 29% of product sales for the nine-month periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company continues to believe that such customers are of high credit quality.

Loss Per Share

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Loss Per Share

The following share-based awards were excluded in the calculation of diluted net loss per common share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine-month periods ended September 30, 2024 and 2023:


	Three and Nine Months Ended September 30,
	2024	2023

Stock options	3,329,460	4,385,555
RSUs	2,175,284	1,755,460

Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 17,489	$ 14,311	$ 47,702	$ 37,976
Inventoriable costs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	497	424	1,405	1,186
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	11,898	9,564	31,923	25,269
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 5,094	$ 4,323	$ 14,374	$ 11,521

Prepaid and Other Assets

9 Months Ended

Sep. 30, 2024

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid and Other Assets

Prepaid expenses and other assets consist of the following (in thousands):


	September 30, 2024		December 31, 2023
Prepaid operating expenses	$	31,400	$	19,465
Production campaign deposits	30,139		15,127
Clinical trial advances	33,389		11,630
Prefunded customer programs	5,563		3,514
Total	100,491		49,736
Less: Current portion	(94,272)		(42,443)
Total other assets	$	6,219	$	7,293

Summary of Significant Accounting Policies - Additional Information (Detail) - segment	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Significant Accounting Policies [Line Items]
Number of operating segments	1
Revenue Benchmark \| Customer Concentration Risk \| Three Major Wholesalers
Significant Accounting Policies [Line Items]
Concentration risk (as a percent)	98.00%
Revenue Benchmark \| Customer Concentration Risk \| Customer One
Significant Accounting Policies [Line Items]
Concentration risk (as a percent)	37.00%	36.00%
Revenue Benchmark \| Customer Concentration Risk \| Customer Two
Significant Accounting Policies [Line Items]
Concentration risk (as a percent)	33.00%	32.00%
Revenue Benchmark \| Customer Concentration Risk \| Customer Three
Significant Accounting Policies [Line Items]
Concentration risk (as a percent)	28.00%	29.00%

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Share-Based Payment Arrangement, Expensed and Capitalized, Amount

Total share-based compensation expense related to all of the Company's share-based awards, including stock options and restricted stock units (“RSUs”), granted to employees and directors recognized during the three and nine-month periods ended September 30, 2024 and 2023, was comprised of the following (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Inventoriable costs	$	497	$	424	$	1,405	$	1,186
Selling, general and administrative	11,898		9,564		31,923		25,269
Research and development	5,094		4,323		14,374		11,521
Total share-based compensation expense	$	17,489	$	14,311	$	47,702	$	37,976

Stock Option Activity

Information regarding the stock options activity, including with respect to grants to employees and directors under the Amended and Restated 2018 Equity Incentive Plan (“the Amended 2018 Plan”) and 2019 Inducement Award Plan (“the 2019 Inducement Plan”) as of September 30, 2024, and changes during the nine-month period then ended, are summarized as follows:


	Number of Shares	Weighted- Average Exercise Price		Weighted- Average Contractual Life
Outstanding at December 31, 2023	4,239,982	$	28.22	5.2 years
Options granted 2024	34,539
Options exercised 2024	(933,601)
Options canceled or expired 2024	(11,460)
Outstanding at September 30, 2024	3,329,460	$	30.74	5.2 years
Vested and expected to vest at September 30, 2024	3,329,460	$	30.74
Exercisable at September 30, 2024	2,968,706	$	28.00	4.8 years

Summary of Information Regarding RSU Activity

Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the nine-month period ended September 30, 2024 is summarized as follows:


	Number of Shares	Weighted-Average Grant Date Fair Value Per Share		Weighted- Average Contractual Life
Outstanding at December 31, 2023	1,645,130	$	48.92	1.0 years
Time-based RSUs granted in 2024	1,100,255
Time-based RSUs vested in 2024	(732,992)
Time-based RSUs cancelled in 2024	(61,611)
Outstanding at September 30, 2024	1,950,782	$	60.35	1.2 years

Organization	9 Months Ended
Organization	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiary, ITI, Inc. (“ITI”), is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. In December 2019, CAPLYTA® (lumateperone) was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA in March 2020. In December 2021, CAPLYTA was approved by the FDA for the treatment of bipolar depression in adults (42 mg/day) and the Company initiated the commercial launch of CAPLYTA for the treatment of bipolar depression. Additionally, in April 2022, the FDA approved two additional dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg capsules for patients with moderate or severe hepatic impairment (Child-Pugh class B or C). The commercial launch of these special population doses occurred in August 2022. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults and for the treatment of bipolar depression in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia and bipolar depression. In April 2024, the Company completed a public offering of common stock in which the Company sold 7,876,713 shares of common stock at a public offering price of $73.00 per share for aggregate gross proceeds of $575.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $543.1 million.

Share-Based Compensation - Additional Information (Detail) $ in Millions	Sep. 30, 2024 USD ($)
Time Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to unvested RSUs	$ 95.5

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Inventory - Schedule of Inventory, Current (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 30,479	$ 38,621
Work in process	13,048	4,277
Finished goods	10,491	7,370
Total	54,018	50,268
Less: Current portion	(23,539)	(11,647)
Total inventory, non-current	30,479	38,621
Inventory subject to supplemental regulatory procedures	$ 8,000	$ 7,700

Share-Based Compensation - Stock Options Activity (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Number of Shares
Outstanding at beginning of period, Number of Shares (in shares)	4,239,982
Options granted, Number of Shares (in shares)	34,539
Options exercised, Number of Shares (in shares)	(933,601)
Options canceled or expired, Number of Shares (in shares)	(11,460)
Outstanding at end of period, Number of Shares (in shares)	3,329,460	4,239,982
Vested or expected to vest at end of period, Number of Shares (in shares)	3,329,460
Exercisable at end of period, Number of Shares (in shares)	2,968,706
Weighted- Average Exercise Price
Outstanding at beginning of period, Weighted-Average Exercise Price (in dollars per share)	$ 28.22
Outstanding at end of period, Weighted-Average Exercise Price (in dollars per share)	30.74	$ 28.22
Vested or expected to vest at end of period, Weighted-Average Exercise Price (in dollars per share)	30.74
Exercisable at end of period, Weighted-Average Exercise Price (in dollars per share)	$ 28.00
Outstanding at end of period, Weighted-Average Contractual Life (in years)	5 years 2 months 12 days	5 years 2 months 12 days
Exercisable at end of period, Weighted-Average Contractual Life (in years)	4 years 9 months 18 days

Loss Per Share - (Tables)

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share


	Three and Nine Months Ended September 30,
	2024	2023

Stock options	3,329,460	4,385,555
RSUs	2,175,284	1,755,460

Fair Value Measurements

9 Months Ended

Sep. 30, 2024

Fair Value Disclosures [Abstract]

Fair Value Measurements

The Company applies the fair value method under ASC Topic 820, Fair Value Measurements and Disclosures. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:

•Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.

•Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.

•Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.

The Company had no assets or liabilities that were measured using prices with significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $225.1 million as of September 30, 2024 and $10.7 million as of December 31, 2023 is included in cash and cash equivalents on the condensed consolidated balance sheets and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of cash held in commercial paper of $6.4 million, corporate bonds of $4.8 million, and U.S. government agency securities of $12.1 million as of September 30, 2024 is included in cash and cash equivalents. The carrying value of cash held in U.S. government agency securities of $2.5 million and certificates of deposit of $60.0 million as of December 31, 2023 is included in cash and cash equivalents.

The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):


			Fair Value Measurements at Reporting Date Using
	September 30, 2024		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money Market Funds	$	225,099	$	225,099	$	—	$	—
U.S. Government Agency Securities	135,946		—		135,946		—
FDIC Certificates of Deposit	980		—		980		—
Certificates of Deposit	60,000		—		60,000		—
Commercial Paper	51,699		—		51,699		—
Corporate Notes/Bonds	316,921		—		316,921		—
	$	790,645	$	225,099	$	565,546	$	—


			Fair Value Measurements at Reporting Date Using
	December 31, 2023		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money Market Funds	$	10,698	$	10,698	$	—	$	—
U.S. Government Agency Securities	150,595		—		150,595		—
FDIC Certificates of Deposit	4,400		—		4,400		—
Certificates of Deposit	60,000		—		60,000		—
Commercial Paper	78,642		—		78,642		—
Corporate Notes/Bonds	119,037		—		119,037		—
	$	423,372	$	10,698	$	412,674	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Investment Securities - Summary of Investment Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	$ 563,917	$ 412,570
Unrealized Gains	1,674	490
Unrealized (Losses)	(45)	(386)
Estimated Fair Value	565,546	412,674
U.S. Government Agency Securities
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	135,801	150,651
Unrealized Gains	158	148
Unrealized (Losses)	(13)	(204)
Estimated Fair Value	135,946	150,595
FDIC Certificates of Deposit
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	980	4,410
Unrealized Gains	0	2
Unrealized (Losses)	0	(12)
Estimated Fair Value	980	4,400
Certificates of Deposit
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	60,000	60,000
Unrealized Gains	0	0
Unrealized (Losses)	0	0
Estimated Fair Value	60,000	60,000
Commercial Paper
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	51,637	78,610
Unrealized Gains	63	59
Unrealized (Losses)	(1)	(27)
Estimated Fair Value	51,699	78,642
Corporate Notes/Bonds
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	315,499	118,899
Unrealized Gains	1,453	281
Unrealized (Losses)	(31)	(143)
Estimated Fair Value	$ 316,921	$ 119,037

Investment Securities (Tables)

9 Months Ended

Sep. 30, 2024

Investments, Debt and Equity Securities [Abstract]

Schedule of Investment Securities

Investment securities consisted of the following (in thousands):


	September 30, 2024
	Amortized Cost		Unrealized Gains		Unrealized (Losses)		Estimated Fair Value
U.S. Government Agency Securities	$	135,801	$	158	$	(13)	$	135,946
FDIC Certificates of Deposit	980		—		—		980
Certificates of Deposit	60,000		—		—		60,000
Commercial Paper	51,637		63		(1)		51,699
Corporate Notes/Bonds	315,499		1,453		(31)		316,921
	$	563,917	$	1,674	$	(45)	$	565,546


	December 31, 2023
	Amortized Cost		Unrealized Gains		Unrealized (Losses)		Estimated Fair Value
U.S. Government Agency Securities	$	150,651	$	148	$	(204)	$	150,595
FDIC Certificates of Deposit	4,410		2		(12)		4,400
Certificates of Deposit	60,000		—		—		60,000
Commercial Paper	78,610		59		(27)		78,642
Corporate Notes/Bonds	118,899		281		(143)		119,037
	$	412,570	$	490	$	(386)	$	412,674

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	175,000,000	175,000,000
Common stock, shares issued (in shares)	105,998,786	96,379,811
Common stock, shares outstanding (in shares)	105,998,786	96,379,811

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total revenues, net	$ 175,375	$ 126,173	$ 481,629	$ 332,271
Operating expenses:
Cost of product sales	15,304	9,129	36,558	23,043
Selling, general and administrative	132,101	105,207	366,760	305,144
Research and development	66,819	41,550	165,835	129,368
Total operating expenses	214,224	155,886	569,153	457,555
Loss from operations	(38,849)	(29,713)	(87,524)	(125,284)
Interest income	12,899	5,498	30,523	14,377
Loss before provision for income taxes	(25,950)	(24,215)	(57,001)	(110,907)
Income tax expense	(374)	(43)	(790)	(188)
Net loss	$ (26,324)	$ (24,258)	$ (57,791)	$ (111,095)
Net loss per common share:
Basic (in dollars per share)	$ (0.25)	$ (0.25)	$ (0.57)	$ (1.16)
Diluted (in dollars per share)	$ (0.25)	$ (0.25)	$ (0.57)	$ (1.16)
Weighted average number of common shares:
Basic (in shares)	105,768,386	96,143,083	102,135,530	95,745,641
Diluted (in share)	105,768,386	96,143,083	102,135,530	95,745,641
Product sales, net
Total revenues, net	$ 175,159	$ 125,810	$ 481,278	$ 330,669
Grant revenue
Total revenues, net	$ 216	$ 363	$ 351	$ 1,602

Investment Securities - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]
Investment securities, available for sale, noncurrent	$ 164.0	$ 77.8
Aggregate related fair value of investments with unrealized losses	66.2	165.2
Aggregate fair value of investments with unrealized losses	1.0	70.1
Continuous unrealized losses, value remaining	65.2	95.1
Debt Securities
Debt Securities, Available-for-Sale [Line Items]
Accrued interest receivable	3.7	$ 2.3
U.S. Government Agency Securities
Debt Securities, Available-for-Sale [Line Items]
Aggregate related fair value of investments with unrealized losses	30.5
Commercial Paper
Debt Securities, Available-for-Sale [Line Items]
Aggregate related fair value of investments with unrealized losses	6.0
Corporate Notes/Bonds
Debt Securities, Available-for-Sale [Line Items]
Aggregate related fair value of investments with unrealized losses	$ 29.7

Right of Use Assets and Lease Liabilities - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2024	May 31, 2024	Sep. 30, 2018
Operating Leased Assets [Line Items]
Term of long term lease	12 months
Vehicle Lease
Operating Leased Assets [Line Items]
Guarantor obligations, value	$ 1,750
NEW YORK
Operating Leased Assets [Line Items]
Term of long term lease			14 years 3 months 18 days
NEW JERSEY
Operating Leased Assets [Line Items]
Term of long term lease		5 years 8 months 12 days

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2024	Oct. 28, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-36274
Entity Registrant Name	INTRA-CELLULAR THERAPIES, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4742850
Entity Address, Address Line One	135 Route 202/206, Suite 6
Entity Address, City or Town	Bedminster
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07921
City Area Code	646
Local Phone Number	440-9333
Title of 12(b) Security	Common Stock
Trading Symbol	ITCI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		106,017,103
Entity Central Index Key	0001567514
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Insider Trading Arrangements	3 Months Ended	9 Months Ended
Insider Trading Arrangements	Sep. 30, 2024 shares	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		•On August 13, 2024, Michael I. Halstead, President, adopted a Rule 10b5-1 Sales Plan having an end date of December 31, 2024. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 41,583 shares of our common stock upon the exercise of stock options. On August 13, 2024, Mr. Halstead adopted a subsequently commencing Rule 10b5-1 Sales Plan with a start date of January 2, 2025 and an end date of April 10, 2025. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of (i) an aggregate of 32,717 shares of our common stock upon the vesting of restricted stock units and (ii) an indeterminate number of shares of our common stock sufficient to cover Mr. Halstead’s tax liability upon the vesting of performance restricted stock units for up to 11,017 shares of our common stock at maximum achievement of the performance vesting conditions. •On September 3, 2024, Sharon Mates, Ph.D., Chairman and Chief Executive Officer, adopted a Rule 10b5-1 Sales Plan having an end date of December 16, 2024. The plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) and provides for the sale of up to an aggregate of 102,697 shares of our common stock upon the exercise of stock options.
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Sharon Mates, Ph.D [Member]
Trading Arrangements, by Individual
Name	Sharon Mates, Ph.D.
Title	Chairman and Chief Executive Officer,
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 3, 2024
Expiration Date	December 16, 2024
Arrangement Duration	104 days
Aggregate Available	102,697	102,697
Michael I. Halstead Trading Arrangement, Aug 13 Plan [Member] \| Michael I. Halstead [Member]
Trading Arrangements, by Individual
Name	Michael I. Halstead
Title	President
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 13, 2024,
Expiration Date	December 31, 2024
Arrangement Duration	140 days
Aggregate Available	41,583	41,583
Michael I. Halstead Trading Arrangement, Jan 2 Plan [Member] \| Michael I. Halstead [Member]
Trading Arrangements, by Individual
Name	Mr. Halstead
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 13, 2024
Expiration Date	April 10, 2025
Arrangement Duration	98 days
Aggregate Available	32,717	32,717

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies License and Royalty Commitments On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and know-how of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds. Under the agreement, the Company has made payments of $10.8 million to BMS related to milestones achieved to date for lumateperone. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of non-royalty payments made in consideration of any sublicense. The agreement extends, and royalties are payable, on a country-by-country and product-by-product basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights. Purchase Commitments The Company enters into certain long-term commitments for goods and services that are outstanding for periods greater than one year. The manufacturing service agreements commit the Company to certain minimum annual purchase commitments for which the Company anticipates making payments within the years 2025 through 2029. As of September 30, 2024, the Company has committed to purchasing production campaigns for various raw materials including active pharmaceutical ingredients (“API”) and its intermediates from each of its supply vendors. The current campaigns are expected to be received into inventory through 2027. Over the course of the vendors’ manufacturing period, the Company will remit payments to each vendor based on the payment plan set forth in their respective agreements. The Company has paid deposits of $30.1 million and $15.1 million as of September 30, 2024 and December 31, 2023, respectively, related to these campaigns. Of the $30.1 million balance as of September 30, 2024, $24.0 million is recorded within prepaid expenses and other current assets as the campaigns are expected to be received within one year of the balance sheet date and $6.1 million is recorded within other assets on the condensed consolidated balance sheet as the campaigns are expected to be received after September 30, 2025. Of the $15.1 million balance as of December 31, 2023, $7.9 million is recorded within prepaid expenses and other current assets and $7.2 million is recorded within other assets on the condensed consolidated balance sheet.

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2024

Fair Value Disclosures [Abstract]

Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities

The fair value measurements of the Company’s cash equivalents and available-for-sale investment securities are identified in the following tables (in thousands):


			Fair Value Measurements at Reporting Date Using
	September 30, 2024		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money Market Funds	$	225,099	$	225,099	$	—	$	—
U.S. Government Agency Securities	135,946		—		135,946		—
FDIC Certificates of Deposit	980		—		980		—
Certificates of Deposit	60,000		—		60,000		—
Commercial Paper	51,699		—		51,699		—
Corporate Notes/Bonds	316,921		—		316,921		—
	$	790,645	$	225,099	$	565,546	$	—


			Fair Value Measurements at Reporting Date Using
	December 31, 2023		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money Market Funds	$	10,698	$	10,698	$	—	$	—
U.S. Government Agency Securities	150,595		—		150,595		—
FDIC Certificates of Deposit	4,400		—		4,400		—
Certificates of Deposit	60,000		—		60,000		—
Commercial Paper	78,642		—		78,642		—
Corporate Notes/Bonds	119,037		—		119,037		—
	$	423,372	$	10,698	$	412,674	$	—

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows used in operating activities
Net loss	$ (57,791)	$ (111,095)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	399	392
Share-based compensation	47,702	37,976
Stock issued for services	64	69
Amortization of premiums and accretion of discounts on investment securities, net	(6,043)	(5,861)
Changes in operating assets and liabilities:
Accounts receivable, net	(31,590)	(27,481)
Inventory	(3,750)	(19,066)
Prepaid expenses and other assets	(50,755)	(16,805)
Accounts payable	(1,114)	218
Accrued and other current liabilities	23,596	8,172
Accrued customer programs	17,363	9,997
Accrued employee benefits	2,132	2,452
Operating lease liabilities, net	(312)	(1,106)
Net cash used in operating activities	(60,099)	(122,138)
Cash flows (used in) provided by investing activities
Purchases of investments	(482,077)	(310,805)
Maturities of investments	297,568	369,192
Purchases of property and equipment	(749)	(268)
Net cash (used in) provided by investing activities	(185,258)	58,119
Cash flows provided by financing activities
Proceeds from exercise of stock options	18,816	14,806
Proceeds from sale of common stock, net	543,086	0
Net cash provided by financing activities	561,902	14,806
Net increase (decrease) in cash, cash equivalents, and restricted cash	316,545	(49,213)
Cash, cash equivalents, and restricted cash at beginning of period	149,517	150,365
Cash, cash equivalents, and restricted cash at end of period	466,062	101,152
Non-cash investing and financing activities
Right of use assets under operating leases	2,548	0
Supplemental cash flow information
Cash paid for taxes	$ 1,364	$ 0

Loss Per Share - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of anti-dilutive securities excluded from computation of earnings per share (in shares)	3,329,460	4,385,555	3,329,460	4,385,555
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of anti-dilutive securities excluded from computation of earnings per share (in shares)	2,175,284	1,755,460	2,175,284	1,755,460

Prepaid and Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid operating expenses	$ 31,400	$ 19,465
Production campaign deposits	30,139	15,127
Clinical trial advances	33,389	11,630
Prefunded customer programs	5,563	3,514
Total	100,491	49,736
Less: Current portion	(94,272)	(42,443)
Total other assets	$ 6,219	$ 7,293

Fair Value Measurements - Additional Information (Detail) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying value of cash held in money market funds	$ 225,100,000	$ 10,700,000
Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Commercial paper, at carrying value	6,400,000
Corporate bonds ,at carrying value	4,800,000
Carrying value of cash held in commercial paper, government securities	12,100,000	2,500,000
Certificates of deposits		60,000,000.0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities measured using quoted prices	0	0
Assets measured using quoted prices	$ 0	$ 0

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 464,312	$ 147,767
Investment securities, available-for-sale	542,250	350,174
Restricted cash	1,750	1,750
Accounts receivable, net	145,608	114,018
Inventory	23,539	11,647
Prepaid expenses and other current assets	94,272	42,443
Total current assets	1,271,731	667,799
Property and equipment, net	2,005	1,654
Right of use assets, net	14,011	12,928
Inventory, non-current	30,479	38,621
Other assets	6,219	7,293
Total assets	1,324,445	728,295
Current liabilities:
Accounts payable	10,338	11,452
Accrued and other current liabilities	51,540	27,944
Accrued customer programs	70,536	53,173
Accrued employee benefits	29,496	27,364
Operating lease liabilities	4,203	3,612
Total current liabilities	166,113	123,545
Operating lease liabilities, non-current	13,506	13,326
Total liabilities	179,619	136,871
Stockholders’ equity:
Common stock, $0.0001 par value: 175,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 105,998,786 and 96,379,811 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	11	10
Additional paid-in capital	2,818,137	2,208,470
Accumulated deficit	(1,674,951)	(1,617,160)
Accumulated comprehensive income	1,629	104
Total stockholders’ equity	1,144,826	591,424
Total liabilities and stockholders’ equity	$ 1,324,445	$ 728,295

Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) - RSUs - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Number of Shares
Outstanding at beginning of year, Number of Shares (in shares)	1,645,130
Time based RSU's granted, Number of Shares (in shares)	1,100,255
Time based RSU's vested, Number of Shares (in shares)	(732,992)
Time based RSU's cancelled, Number of Shares (in shares)	(61,611)
Outstanding at end of year, Number of Shares (in shares)	1,950,782	1,645,130
Weighted-Average Grant Date Fair Value Per Share
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value (in dollars per share)	$ 48.92
Outstanding at end of year, Weighted-Average Grant Date Fair Value (in dollars per share)	$ 60.35	$ 48.92
Restricted stock outstanding, Weighted-Average Contractual Life (in years)	1 year 2 months 12 days	1 year

Right of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Other information
Weighted average remaining lease term (in years)	4 years 8 months 12 days		5 years 3 months 18 days
Weighted average discount rate (as a percent)	8.82%		9.07%
Lease cost
Operating lease cost	$ 3,027	$ 2,921
Variable lease cost	1,254	1,130
Short-term lease cost	1,854	1,757
Total lease cost	$ 6,135	$ 5,808

Inventory

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Inventory

Inventory consists of the following (in thousands):


	September 30, 2024		December 31, 2023
Raw materials	$	30,479	$	38,621
Work in process	13,048		4,277
Finished goods	10,491		7,370
Total	54,018		50,268
Less: Current portion	(23,539)		(11,647)
Total inventory, non-current	$	30,479	$	38,621

As of September 30, 2024 and December 31, 2023, the Company has recorded $8.0 million and $7.7 million, respectively, in inventory on the condensed consolidated balance sheets which is subject to supplemental regulatory procedures but the Company believes it is probable that such inventory has future economic benefit.

Right of Use Assets and Lease Liabilities (Tables)

9 Months Ended

Sep. 30, 2024

Leases [Abstract]

Schedule of Quantitative Information About Operating Leases

The following table presents the weighted average remaining lease term, and the weighted average discount rates related to leases as of September 30, 2024 and December 31, 2023:


	September 30, 2024		December 31, 2023
Other information
Weighted average remaining lease term	4.7 years		5.3 years
Weighted average discount rate	8.82	%	9.07	%

The following table presents the lease cost for the nine-month periods ended September 30, 2024 and 2023 (in thousands):


	Nine Months Ended September 30,
	2024		2023
Lease cost
Operating lease cost	$	3,027	$	2,921
Variable lease cost	1,254		1,130
Short-term lease cost	1,854		1,757
	$	6,135	$	5,808

Schedule Of Maturity Analysis Under Lease Agreements

Maturity analysis under the lease agreements is as follows (in thousands):


Three months ending December 31, 2024	$	1,112
Year ending December 31, 2025	4,436
Year ending December 31, 2026	4,513
Year ending December 31, 2027	4,573
Year ending December 31, 2028	4,707
Thereafter	2,457
Total	21,798
Less: Present value discount	(4,089)
Total operating lease liability	17,709
Less: Current portion	(4,203)
Operating lease liabilities, non-current	$	13,506

Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
Three months ending December 31, 2024	$ 1,112
Year ending December 31, 2025	4,436
Year ending December 31, 2026	4,513
Year ending December 31, 2027	4,573
Year ending December 31, 2028	4,707
Thereafter	2,457
Total	21,798
Less: Present value discount	(4,089)
Total operating lease liability	17,709
Less: Current portion	(4,203)	$ (3,612)
Operating lease liabilities, non-current	$ 13,506	$ 13,326

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands		9 Months Ended	232 Months Ended
	May 31, 2005	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Purchase Commitment
Purchase Commitment, Excluding Long-Term Commitment [Line Items]
Cash paid		$ 30,100	$ 30,100	$ 15,100
Other current assets		24,000	24,000	7,900
Other assets		6,100	6,100	$ 7,200
Product \| Bristol-Myers Squibb Company
Purchase Commitment, Excluding Long-Term Commitment [Line Items]
Company made an upfront payment			10,800
Payment of milestone amount		$ 5,000	$ 5,000
Obliged to make milestone payments	$ 14,750
License expiration period		10 years
Product \| Bristol-Myers Squibb Company \| Minimum
Purchase Commitment, Excluding Long-Term Commitment [Line Items]
Royalty payment, percentage (as a percent)	5.00%
Product \| Bristol-Myers Squibb Company \| Maximum
Purchase Commitment, Excluding Long-Term Commitment [Line Items]
Royalty payment, percentage (as a percent)	9.00%

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 464,312	$ 147,767	$ 99,402
Restricted cash	1,750	1,750	1,750
Total cash, cash equivalents and restricted cash	$ 466,062	$ 149,517	$ 101,152	$ 150,365

Prepaid and Other Assets (Tables)

9 Months Ended

Sep. 30, 2024

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Assets

Prepaid expenses and other assets consist of the following (in thousands):


	September 30, 2024		December 31, 2023
Prepaid operating expenses	$	31,400	$	19,465
Production campaign deposits	30,139		15,127
Clinical trial advances	33,389		11,630
Prefunded customer programs	5,563		3,514
Total	100,491		49,736
Less: Current portion	(94,272)		(42,443)
Total other assets	$	6,219	$	7,293

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net loss	$ (26,324)	$ (16,220)	$ (15,247)	$ (24,258)	$ (42,784)	$ (44,053)	$ (57,791)	$ (111,095)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Organization - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	9 Months Ended
	Apr. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Shares sold (in shares)	7,876,713
Offering price (in dollars per share)	$ 73.00
Aggregate gross proceeds	$ 575,000
Proceeds from sale of common stock, net	$ 543,100	$ 543,086	$ 0

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net loss	$ (26,324)	$ (24,258)	$ (57,791)	$ (111,095)
Other comprehensive gain:
Unrealized gain on investment securities	2,297	933	1,525	2,855
Comprehensive loss	$ (24,027)	$ (23,325)	$ (56,266)	$ (108,240)

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly owned subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs primarily in psychiatric and neurological disorders. Recent Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, requiring public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are also required to apply the disclosure requirements. The standard is effective for annual reporting periods beginning after December 15, 2023, and for interim reporting periods beginning January 1, 2025, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on its consolidated financial statements and related disclosures. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. Significant Accounting Policies The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalents and investment securities held at financial institutions. For the nine-month period ended September 30, 2024, 98% of product sales were generated from three major industry wholesalers. Three individual customers accounted for approximately 37%, 33%, and 28% as well as 36%, 32%, and 29% of product sales for the nine-month periods ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the Company continues to believe that such customers are of high credit quality. Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.

Share-Based Compensation

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Inventoriable costs	$	497	$	424	$	1,405	$	1,186
Selling, general and administrative	11,898		9,564		31,923		25,269
Research and development	5,094		4,323		14,374		11,521
Total share-based compensation expense	$	17,489	$	14,311	$	47,702	$	37,976


	Number of Shares	Weighted- Average Exercise Price		Weighted- Average Contractual Life
Outstanding at December 31, 2023	4,239,982	$	28.22	5.2 years
Options granted 2024	34,539
Options exercised 2024	(933,601)
Options canceled or expired 2024	(11,460)
Outstanding at September 30, 2024	3,329,460	$	30.74	5.2 years
Vested and expected to vest at September 30, 2024	3,329,460	$	30.74
Exercisable at September 30, 2024	2,968,706	$	28.00	4.8 years

The fair value of the time-based RSUs is based on the closing price of the Company’s common stock on the date of grant. Information regarding the time-based RSU activity, including with respect to grants to employees under the Amended 2018 Plan and 2019 Inducement Plan, and changes during the nine-month period ended September 30, 2024 is summarized as follows:


	Number of Shares	Weighted-Average Grant Date Fair Value Per Share		Weighted- Average Contractual Life
Outstanding at December 31, 2023	1,645,130	$	48.92	1.0 years
Time-based RSUs granted in 2024	1,100,255
Time-based RSUs vested in 2024	(732,992)
Time-based RSUs cancelled in 2024	(61,611)
Outstanding at September 30, 2024	1,950,782	$	60.35	1.2 years

As of September 30, 2024, there were $95.5 million of unrecognized compensation costs estimated related to unvested time-based RSUs.

Investment Securities

9 Months Ended

Sep. 30, 2024

Investments, Debt and Equity Securities [Abstract]

Investment Securities

Investment securities consisted of the following (in thousands):


	September 30, 2024
	Amortized Cost		Unrealized Gains		Unrealized (Losses)		Estimated Fair Value
U.S. Government Agency Securities	$	135,801	$	158	$	(13)	$	135,946
FDIC Certificates of Deposit	980		—		—		980
Certificates of Deposit	60,000		—		—		60,000
Commercial Paper	51,637		63		(1)		51,699
Corporate Notes/Bonds	315,499		1,453		(31)		316,921
	$	563,917	$	1,674	$	(45)	$	565,546


	December 31, 2023
	Amortized Cost		Unrealized Gains		Unrealized (Losses)		Estimated Fair Value
U.S. Government Agency Securities	$	150,651	$	148	$	(204)	$	150,595
FDIC Certificates of Deposit	4,410		2		(12)		4,400
Certificates of Deposit	60,000		—		—		60,000
Commercial Paper	78,610		59		(27)		78,642
Corporate Notes/Bonds	118,899		281		(143)		119,037
	$	412,570	$	490	$	(386)	$	412,674

The Company has classified all of its investment securities as available-for-sale, including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2024 and December 31, 2023, the Company held $164.0 million and $77.8 million, respectively, of available-for-sale investment securities with contractual maturity dates more than one year and less than two years, with the remainder of the available-for-sale investment securities having contractual maturity dates less than one year. Accrued interest receivable from investment securities as of September 30, 2024 and December 31, 2023 was $3.7 million and $2.3 million, respectively, and are included within prepaid expenses and other current assets.

The aggregate related fair value of investments with unrealized losses as of September 30, 2024 was $66.2 million, which consisted of $30.5 million of U.S. government agency securities, $6.0 million of commercial paper, and $29.7 million of corporate notes/bonds. $1.0 million of the aggregate fair value of investments with unrealized losses as of September 30, 2024 has been held in a continuous unrealized loss position for over 12 months, with the remaining $65.2 million held in a continuous unrealized loss position for less than 12 months. As of December 31, 2023, the aggregate related fair value of investments with unrealized losses was $165.2 million. $70.1 million of the aggregate fair value of investments with unrealized losses as of December 31, 2023 had been held in a continuous unrealized loss position for more than 12 months, with the remaining $95.1 million held in a continuous unrealized loss position for less than 12 months.

The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.

Fair Value Measurements - Schedule of Fair Value Measurements of Cash Equivalents (Detail) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	$ 0	$ 0
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	790,645,000	423,372,000
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	225,099,000	10,698,000
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	565,546,000	412,674,000
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	225,099,000	10,698,000
Fair Value, Measurements, Recurring \| Money Market Funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	225,099,000	10,698,000
Fair Value, Measurements, Recurring \| Money Market Funds \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| Money Market Funds \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| U.S. Government Agency Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	135,946,000	150,595,000
Fair Value, Measurements, Recurring \| U.S. Government Agency Securities \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| U.S. Government Agency Securities \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	135,946,000	150,595,000
Fair Value, Measurements, Recurring \| U.S. Government Agency Securities \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| FDIC Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	980,000	4,400,000
Fair Value, Measurements, Recurring \| FDIC Certificates of Deposit \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| FDIC Certificates of Deposit \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	980,000	4,400,000
Fair Value, Measurements, Recurring \| FDIC Certificates of Deposit \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| Certificates of Deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	60,000,000	60,000,000
Fair Value, Measurements, Recurring \| Certificates of Deposit \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| Certificates of Deposit \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	60,000,000	60,000,000
Fair Value, Measurements, Recurring \| Certificates of Deposit \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	51,699,000	78,642,000
Fair Value, Measurements, Recurring \| Commercial Paper \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| Commercial Paper \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	51,699,000	78,642,000
Fair Value, Measurements, Recurring \| Commercial Paper \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| Corporate Notes/Bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	316,921,000	119,037,000
Fair Value, Measurements, Recurring \| Corporate Notes/Bonds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	0	0
Fair Value, Measurements, Recurring \| Corporate Notes/Bonds \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	316,921,000	119,037,000
Fair Value, Measurements, Recurring \| Corporate Notes/Bonds \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale investment securities	$ 0	$ 0